15 July 2014 by Ardeschir Ghofrani

Imatinib for PAH. Failed Therapy or Failed Trial Design?

All credits to Prof. A. Ghofrani FPVRI, Professor of Medicine at the University of Giessen, in Giessen, Germany

Presented at the 1st Annual Drug Discovery and Development Symposium, July 14-15th 2014, Bethesda, USA

 

Additional key-words:  imatinib,monocrotaline,pulmonary vascular resistance,IMPRES,trial design

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI
standard-example-image.jpg